New Drug Import Program Is Under Consideration

The FDA will test a secure supply-chain pilot program for imported drugs and active pharmaceutical ingredients (APIs) to determine whether such a plan is practical. Companies participating in the pilot program would have a greater chance of gaining expedited entry for their imported finished drugs or APIs, according to a Thursday Federal Register notice.
Drug Industry Daily